DDInter1382 DDInter1658
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Palonosetron {u} (Compound) resembles {v} (Compound) Praziquantel
Palonosetron {u} (Compound) binds {v} (Gene) HTR3A
Palonosetron {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 3 Receptor Antagonists
Palonosetron {u} (Compound) causes {v} (Side Effect) Malnutrition
Palonosetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Palonosetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ezogabine
Palonosetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Palonosetron {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Palonosetron {u} may lead to a major life threatening interaction when taken with {v} Mirtazapine
Palonosetron (Compound) resembles Praziquantel (Compound)
Palonosetron (Compound) binds HTR3A (Gene)
Palonosetron (Compound) is included by Serotonin 3 Receptor Antagonists (Pharmacologic Class)
Palonosetron (Compound) causes Malnutrition (Side Effect)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole
Palonosetron may lead to a major life threatening interaction when taken with Lefamulin
Palonosetron may lead to a major life threatening interaction when taken with Mirtazapine